Please assess the completion status of the following clinical trial:

Trial Title: S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed multiple myeloma requiring treatment~  * Smoldering myeloma with evidence of progressive disease requiring chemotherapy~    * More than 25% increase in M component levels and/or Bence-Jones excretion or symptom development~ * Non-secretory patients with at least 30% bone marrow plasmacytosis~* No IgM peaks unless there is evidence of more than 30% bone marrow plasmacytosis or more than 3 lytic lesions~PATIENT CHARACTERISTICS:~Age~* 18 to 65~Performance status~* Zubrod 0-2 OR~* Zubrod 3-4 based solely on bone pain~Life expectancy~* Not specified~Hematopoietic~* No untreated, unresolved symptomatic hyperviscosity~Hepatic~* Hepatitis B negative~Renal~* Creatinine no greater than 3 mg/dL if in renal failure and on dialysis (after hydration and/or correction of hypercalcemia)~Cardiovascular~* No history of chronic cerebrovascular accident~* No myocardial infarction within the past 6 months~* No unstable angina~* No congestive heart failure that is difficult to control~* No uncontrollable hypertension~* No cardiac arrhythmia that is difficult to control~Pulmonary~* No history of chronic obstructive or chronic restrictive pulmonary disease~* No untreated, unresolved pneumonia~* Pulmonary function tests (PFTs) at least 50% of predicted~* DLCO at least 50% of predicted~* Arterial partial pressure of oxygen greater than 70 if unable to complete PFTs due to bone pain or fracture~Other~* HIV negative~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No untreated, unresolved pathologic fractures~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use at least 2 highly effective methods of contraception for 4 weeks before, during, and for at least 4 weeks after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No more than 8 weeks of prior thalidomide therapy~Chemotherapy~* No prior chemotherapy for this disease~Endocrine therapy~* Prior steroid therapy allowed provided treatment duration was no more than 2 weeks~Radiotherapy~* No prior radiotherapy to more than 50% of the pelvis~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: EXPERIMENTAL): thalidomide/dexamethasone followed by tandem melphalan peripheral blood stem cell transplantation (with cyclophosphamide and filgrastim or sargramostim support) and prednisone/thalidomide maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).